## Clinical Diagnosis: Warfarin-Associated Intracerebral Hemorrhage (ICH) ### Key Clinical Features **Key Point:** This patient has anticoagulant-associated lobar ICH (gray-white matter junction location is typical for lobar bleeds). The supratherapeutic INR (4.2) is the culprit. Management priorities are: (1) reverse anticoagulation, (2) control ICP, (3) prevent hematoma expansion. **High-Yield:** Warfarin-associated ICH has a higher mortality and morbidity than hypertensive ICH because of ongoing anticoagulation and risk of hematoma expansion. Rapid reversal of INR is critical. ### Management Algorithm for Warfarin-Associated ICH ```mermaid flowchart TD A[Warfarin-associated ICH]:::outcome --> B{INR level?}:::decision B -->|INR > 4| C[FFP 10-15 mL/kg]:::action B -->|Any INR| D[Vitamin K 10 mg IV]:::action C --> E[Vitamin K 10 mg IV]:::action D --> F{Reversal agent available?}:::decision F -->|Idarucizumab available| G[Idarucizumab 5 g IV]:::action F -->|Not available| H[Continue FFP + Vitamin K]:::action E --> I[Head elevation 30°]:::action H --> I G --> I I --> J[Osmotic therapy: Mannitol or HTS]:::action J --> K[Monitor ICP, avoid hyperthermia]:::action K --> L[Reassess CT at 24 hrs]:::outcome ``` ### Why FFP + Vitamin K (Not Idarucizumab Alone) | Agent | Mechanism | Onset | Duration | Use Case | |-------|-----------|-------|----------|----------| | **FFP** | Replaces vitamin K-dependent factors (II, VII, IX, X) | Immediate (15–30 min) | 4–6 hrs | First-line, always use | | **Vitamin K** | Induces hepatic synthesis of vitamin K-dependent factors | Slow (12–24 hrs) | Days | Long-term reversal, must combine with FFP | | **Idarucizumab** | Direct thrombin inhibitor reversal (dabigatran only) | Immediate | 24 hrs | NOT indicated for warfarin; only for dabigatran | | **PCC** | Prothrombin complex concentrate (factors II, VII, IX, X) | Immediate | 12–24 hrs | Preferred over FFP if available (less volume) | **Warning:** Idarucizumab is a direct thrombin inhibitor reversal agent used ONLY for dabigatran, not warfarin. This is a high-yield trap. ### Comprehensive ICH Management **Key Point:** Beyond anticoagulation reversal, ICH management includes: 1. **Anticoagulation reversal** (as above) 2. **Blood pressure control:** Target SBP < 140 mmHg (reduces hematoma expansion) 3. **Elevated head position:** 30° elevation to reduce ICP 4. **Osmotic therapy:** Mannitol (0.25–1 g/kg) or hypertonic saline (3% or 23.4%) to reduce cerebral edema 5. **Avoid hyperthermia:** Core temperature < 37.5°C 6. **Seizure prophylaxis:** Levetiracetam (lobar ICH has ~10% seizure risk) 7. **Repeat imaging:** CT at 24 hrs to assess hematoma expansion **Clinical Pearl:** Hematoma expansion occurs in 30–40% of ICH cases in the first 24 hours, especially if anticoagulated. Early reversal and BP control reduce this risk. ### Why Not Idarucizumab? Idarucizumab is a monoclonal antibody fragment that reverses dabigatran (a direct thrombin inhibitor), not warfarin. Warfarin inhibits vitamin K-dependent factors, so reversal requires FFP ± vitamin K or prothrombin complex concentrate (PCC). ### Why Not Heparin? **Warning:** Heparin is contraindicated in acute ICH because it increases bleeding and hematoma expansion. It may be considered weeks later if the patient requires anticoagulation for AF, but not acutely. ### Why Not Immediate Craniectomy? Decompressive craniectomy is reserved for: - Large supratentorial ICH (> 30 mL) with mass effect and deteriorating consciousness - Cerebellar ICH (> 3 cm) with brainstem compression or hydrocephalus This patient has a lobar bleed without midline shift and stable GCS (12), so medical management is appropriate first. Craniectomy would be considered if she deteriorates despite maximal medical therapy. [cite:Harrison 21e Ch 434] [cite:Stroke Council Guidelines 2019]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.